Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001072613-25-000670
Filing Date
2025-08-19
Accepted
2025-08-19 18:53:37
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 26215
2 AGREEMENT exh1.htm EX-1 41721
3 SCHEDULE A exh2.htm EX-2 12706
4 POWER OF ATTORNEY exh3.htm EX-3 25905
  Complete submission text file 0001072613-25-000670.txt   108491
Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
New Enterprise Associates 14, L.P. (Filed by) CIK: 0001544328 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231

Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom 44 1235 430000
Adaptimmune Therapeutics PLC (Subject) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88833 | Film No.: 251233431
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)